Asterias Biotherapeutics (AST) Reports In-Line Q4 EPS

Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $1.07 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
• Beam Global reports Q2 2026 revenue above $8.5M, up 170% from Q1
• Buy Apple stock ahead of expected $200 iPhone price hikes: Morgan Stanley